A review. Regulation of gene expression represents a major component in antidepressant drug action. The effect of antidepressant treatments on the function of cAMP-responsive element binding protein (CREB), a transcription factor that regulates expression of several genes involved in neuroplasticity, cell survival, and cognition, has been extensively studied. Although there is general agreement that chronic antidepressants stimulate CREB function, conflicting results suggest that different effects may depend on drug type, drug dosage, and different exptl. paradigms. CREB function is activated by a vast array of physiol. stimuli, conveyed through a no. of signaling pathways acting in concert, but thus far the effects of antidepressants on CREB have been analyzed mostly with regard to the cAMP-protein kinase A pathway. A growing body of data shows that other major pathways, such as the calcium/calmodulin-dependent kinase and the mitogen-activated kinase cascades, are involved in activity-dependent regulation of gene expression and may also be implicated in the mechanism of action of antidepressants. In this article the available evidence is reviewed with an attempt to identify the reasons for exptl. discrepancies and possible directions for future research. Particular emphasis is given to the regulation of brain-derived neurotrophic factor (BDNF), a CREB-regulated gene, which has been implicated in both the pathophysiol. and pharmacol. of mood disorders. The array of different results obtained by various groups is analyzed with an eye on recent advancements in the regulation of BDNF transcription, in an attempt to understand better the mechanisms of drug action and dissect mol. requirements for faster and more efficient antidepressant treatment
Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants : a critical overview / D. Tardito, J. Perez, E. Tiraboschi, L. Musazzi, G.A. Racagni, M. Popoli. - In: PHARMACOLOGICAL REVIEWS. - ISSN 0031-6997. - 58:1(2006), pp. 115-134.
Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants : a critical overview
D. TarditoPrimo
;E. Tiraboschi;L. Musazzi;G.A. RacagniPenultimo
;M. PopoliUltimo
2006
Abstract
A review. Regulation of gene expression represents a major component in antidepressant drug action. The effect of antidepressant treatments on the function of cAMP-responsive element binding protein (CREB), a transcription factor that regulates expression of several genes involved in neuroplasticity, cell survival, and cognition, has been extensively studied. Although there is general agreement that chronic antidepressants stimulate CREB function, conflicting results suggest that different effects may depend on drug type, drug dosage, and different exptl. paradigms. CREB function is activated by a vast array of physiol. stimuli, conveyed through a no. of signaling pathways acting in concert, but thus far the effects of antidepressants on CREB have been analyzed mostly with regard to the cAMP-protein kinase A pathway. A growing body of data shows that other major pathways, such as the calcium/calmodulin-dependent kinase and the mitogen-activated kinase cascades, are involved in activity-dependent regulation of gene expression and may also be implicated in the mechanism of action of antidepressants. In this article the available evidence is reviewed with an attempt to identify the reasons for exptl. discrepancies and possible directions for future research. Particular emphasis is given to the regulation of brain-derived neurotrophic factor (BDNF), a CREB-regulated gene, which has been implicated in both the pathophysiol. and pharmacol. of mood disorders. The array of different results obtained by various groups is analyzed with an eye on recent advancements in the regulation of BDNF transcription, in an attempt to understand better the mechanisms of drug action and dissect mol. requirements for faster and more efficient antidepressant treatmentFile | Dimensione | Formato | |
---|---|---|---|
Pharmacol. Rev.06.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
213.29 kB
Formato
Adobe PDF
|
213.29 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.